A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- KRAS Activating Mutation
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate safety and tolerability and efficacy of VS-6766 versus VS-6766 in combination with defactinib in subjects with KRAS-MT NSCLC following treatment with an appropriate platinum-based regimen and an approved immune c...
This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate safety and tolerability and efficacy of VS-6766 versus VS-6766 in combination with defactinib in subjects with KRAS-MT NSCLC following treatment with an appropriate platinum-based regimen and an approved immune checkpoint inhibitor (CPI).
Tracking Information
- NCT #
- NCT04620330
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ross Camidge, MD, PhD University of Colorado, Denver Study Director: Hagop Youssoufian, MD Verastem, Inc.
Get Well Soon